Aragen Bioscience, Inc.

15 articles about Aragen Bioscience, Inc.

• Oragenics Inc. and Aragen Bioscience Enter Agreement to Accelerate Development of TerraCoV2, a SARS-CoV-2 (COVID 19) Vaccine Candidate

  5/19/2020

  Oragenics, Inc. (NYSE American: OGEN) , (the “Company” or “Oragenics”), today announced, that through its wholly-owned subsidiary, Noachis Terra, it has entered into an agreement with Aragen Bioscience, a leading contract research organization focused on accelerating pre-clinical biologics product development, to advance TerraCov2 the Company’s SARS CoV-2 vaccine candidate. Under the terms of the ag

• Avid Bioservices and Aragen Bioscience Enter Agreement to Offer Biotechnology and Pharmaceutical Clients Integrated Solution for Cell Line and Process Development through Commercial Manufacturing

  5/6/2020

  Full Service “Sequence-to-Manufacturing” Offering Designed to Drive Efficiencies and Reduce Overall Timelines for Delivering Early-Stage CGMP Bulk Drug Substances

• Aragen Bioscience, Inc. and University of Technology, Sydney Enter Into MoU to Support and Accelerate Biologics R&D in Australia

  3/3/2020

  Aragen Bioscience, Inc, a fully owned subsidiary of GVK BIO and a leading large molecule CRO, and University of Technology Sydney, the top-ranked young university in Australia, are pleased to announce a collaboration to accelerate biologics R&D in Australia.

• Serum Institute and Aragen Bioscience Announce Collaboration on Vaccine Development

  1/8/2020

  Aragen Bioscience, Inc and Serum Institute of India Pvt. Ltd. are pleased to announce a collaboration for the development of multiple stable cell lines to support Serum’s HIV program.

• GVK BIO Announces the Appointment of Axel Schleyer, Ph.D. as Chief Executive Officer, Aragen Bioscience, Inc.

  5/8/2019

  GVK BIO is pleased to announce the appointment of Dr. Axel Schleyer as Chief Executive Officer, Aragen Bioscience Inc.

• Aragen Bioscience, Inc. Announces Ground Breaking On State Of The Art Research Facility

  1/28/2016

• Aragen Bioscience, Inc. Announces Licensing Agreement For Protein Production Technology From ProteoNic

  9/9/2015

• Aragen Bioscience, Inc. And Transposagen Biopharmaceuticals, Inc. Partner To Launch FUT8 Knockout CHO DG44 Cell Line Development Services

  6/16/2015

• Aragen Bioscience, Inc. and Innovent Biologics Announce Collaboration for Biotherapeutic Product Development

  4/3/2013

• Aragen Bioscience, Inc. Successfully Completes Antibody Humanization Project

  5/2/2012

• Aragen Bioscience, Inc. Announces Offering of GLP Services

  6/24/2011

• Aragen Bioscience, Inc. Announces Offering of GLP Services

  6/23/2011

• Aragen Bioscience, Inc. Awarded Three Preclinical Development NIAID Subcontracts

  4/5/2011

• Aragen Bioscience, Inc. and CEVEC Sign License Agreement for Human CAP(R) and CAP-T(TM) Technology

  4/30/2010

• Bone Biologics Announces UCB-1 (NELL-1) Bone Growth Protein Production Process With Aragen Bioscience, Inc.

  2/24/2009